References
Scott LM, Campbell PJ, Baxter EJ, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood. 2005;106:2920–1.
Kramer A, Reiter A, Kruth J, et al. JAK2–V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol. 2007;8:658–60.
Hussein K, Bock O, Seegers A, Flasshove M, et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood. 2007;109:4106–7.
Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.
Bornhauser M, Mohr B, Oelschlaegel U, et al. Concurrent JAK2 (V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia. 2007;21:1824–6.
Busche G, Hussein K, Bock O, Kreipe H. Insights into JAK2–V617F mutation in CML. Lancet Oncol. 2007;8:863–4.
Bocchia M, Vannucchi AM, Gozzetti A, et al. Insights into JAK2–V617F mutation in CML. Lancet Oncol. 2007;8:864–6.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
de Conchon, M.R.M., Costa, J.L., Novaes, M.M.Y. et al. Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia. Int J Hematol 88, 243–245 (2008). https://doi.org/10.1007/s12185-008-0131-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-008-0131-2